EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer

Olesya Kuznetsova iD, Albina Zagidullina iD, Natalia Drobot, Aleksander Prokopiev iD, Maxim Ivanov, Mikhail Fedyanin iD, Zaman Mamedli iD, Vyacheslav Aliev, Andrey Polynovsky iD, Khasan Dzhumabaev, Aleksander Aniskin, Anna Stroganova und 2 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po-25-00602 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Olesya Kuznetsova und 13 weiteren Autor:innen. Beteiligte Einrichtung: Federal State Budgetary Institution «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia, Mosc…. Hauptthemen laut MEDLINE: Microsatellite Instability, Colorectal Neoplasms, Neoadjuvant Therapy, Immunotherapy. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Although adjuvant chemotherapy is standard for locally advanced colon cancer, defective mismatch repair (dMMR)/microsatellite instability (MSI) tumors show high sensitivity to immune checkpoint inhibitors. We aimed to investigate the efficacy of the PD-1 inhibitor prolgolimab in this setting. METHODS We conducted phase II nonrandomized open-label clinical trial (ClinicalTrials.gov identifier: NCT06428487 ) in patients with locally advanced colorectal cancer (CRC) and dMMR/MSI. Prolgolimab (1 mg/kg) was administered once every 2 weeks, and surgery was performed after 6 months of immunotherapy. In case of surgical treatment refusal, the systemic treatment proceeded for 1 year. The primary end point was the rate of pathologic complete response (pCR, in operated cases) + clinical complete response (cCR, in nonoperated cases). Secondary end points included pCR, major pathologic response (MPR), objective response (ORR) rates, safety, disease-free survival (DFS), and overall survival. RESULTS Of the 30 enrolled, 26 (86.6%) patients underwent surgery after the end of immunotherapy. The study met its primary end point, with 17 (56.7%) of 30 patients achieving pCR (n = 16) + cCR (n = 1 as nonoperated case). According to histologic examination, an MPR (TRG 1-2) was observed in 21 (80.8%) of 26 patients, including 16 (61.6%) patients with pCR. Radiographic ORR was 89.7%, and cCR was observed in six cases (20.7%, five patients underwent surgery further). Three patients with low rectal primary tumors refused to undergo a surgical treatment. The median follow-up was 19 months (range, 13-32). The 18-month DFS was 90%: two progressions and one unrelated death were detected. Grade 3-4 immune-related adverse effects were recorded in one (3.3%) patient. CONCLUSION The use of prolgolimab in locally advanced dMMR/MSI CRC is associated with high rates of pCR and cCR, allowing for further exploration of organ-sparing approaches in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Microsatellite InstabilityColorectal NeoplasmsNeoadjuvant TherapyImmunotherapyAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedAgedDNA Mismatch RepairAdult

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Federal State Budgetary Institution «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia, Moscow, Russia.
  • OncoAtlas LLC, Moscow, Russia.
  • I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • State Budgetary Healthcare Institution "Medical Clinical Scientific Center" "Kommunarka" of the Moscow Department of Health, Moscow, Russia.
  • A.S.Loginov Moscow Clinical Scientific Centre, Moscow, Russia.

ORCID-Profile: Olesya Kuznetsova, Albina Zagidullina, Aleksander Prokopiev, Mikhail Fedyanin, Zaman Mamedli, Andrey Polynovsky, Ivan Karasev, Alexey Tryakin

Zitieren

APA

Kuznetsova, O., Zagidullina, A., Drobot, N., Prokopiev, A., Ivanov, M., Fedyanin, M., Mamedli, Z., Aliev, V., Polynovsky, A., Dzhumabaev, K., Aniskin, A., Stroganova, A., Karasev, I., & Tryakin, A. (2025). Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-25-00602

Vancouver

Kuznetsova O, Zagidullina A, Drobot N, Prokopiev A, Ivanov M, Fedyanin M, et al. Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer. JCO Precision Oncology. 2025. doi:10.1200/po-25-00602

BibTeX
@article{Kuznetsova2025,
  author = {Kuznetsova, Olesya and Zagidullina, Albina and Drobot, Natalia and Prokopiev, Aleksander and Ivanov, Maxim and Fedyanin, Mikhail and Mamedli, Zaman and Aliev, Vyacheslav and Polynovsky, Andrey and Dzhumabaev, Khasan and Aniskin, Aleksander and Stroganova, Anna and Karasev, Ivan and Tryakin, Alexey},
  title = {Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-25-00602}
}
Kostenlos starten →